New Strategy Could Lead to New Anticancer Treatments

June 25, 2019

Technion researchers, in collaboration with Japanese and American scientists, have developed an innovative strategy for eliminating cancer cells. The research was recently published in Nature Chemistry by Professor Ashraf Brik of the Schulich Faculty of Chemistry at the Technion, Prof. Hiro Suga of the University of Tokyo, Nobel Laureate in Chemistry and Distinguished Prof. Aaron Ciechanover of the Technion’s Rappaport Faculty of Medicine, and Prof. David Fushman of the University of Maryland’s Department of Chemistry and Biochemistry.

The new study is a dramatic milestone in the application of the discovery of the ubiquitin system that led to the 2004 Nobel Prize in Chemistry for Distinguished Professors Avram Hershko and Aaron Ciechanover, and Dr. Irwin Rose. The trio of researchers discovered how unique proteins, which they called the “ubiquitin proteins,” label defective proteins with a “death tag” that leads to their breakdown in protease, also known as the “cellular garbage can.”

It is now clear that the proper functioning of the ubiquitin system is essential for the healthy functioning of the organism, not only in the context of the breakdown of used proteins, but also in many other functions. Disruptions in this system cause serious diseases, including various cancers, amyotrophic lateral sclerosis (Lou Gehrig’s disease), cystic fibrosis, Parkinson’s disease, and other neurodegenerative disorders.

The discovery of ubiquitin paved the way for a new field of research, and many research groups around the world have been working on the ubiquitin system and harnessing it for developing innovative medical treatments. To date, four such drugs have been approved for the treatment of cancer in general and multiple myeloma in particular. These drugs have already saved the lives of many people around the world, but according to Prof. Brik, “the progress in the study of the ubiquitin system and the development of drugs based on its understanding are very slow relative to its potential.”

The first stage in the normal natural activity of the ubiquitin system is the creation of chains of ubiquitin (polyUB chains) that later label the proteins to be broken down. The problem is that when cancer develops in the body, cancer cells know how to carry out manipulation in the ubiquitin system and exploit it for survival and proliferation.

The strategy developed by the group headed by Prof. Brik was designed to neutralize the ability of the malignancy to perform the same manipulation. This strategy is based on an unprecedented combination of Prof. Brik’s skill in producing ubiquitin chains using advanced chemical methods and Prof. Suga’s method of creating very large libraries of molecules called cyclic peptides. As part of the collaboration, the researchers discovered how these cylic peptides bind to the ubiquitin chains and thus inhibit the breakdown of proteins that help the cancer to grow and thrive. They believe the strategy they have developed will pave the way for new types of anticancer treatment based on cyclic peptides.

Prof. Ashraf Brik holds the Jordan and Irene Tark Chair in the Schulich Faculty of Chemistry. The current study is supported by the US National Institutes of Health (NIH), the Miriam and Sheldon Adelson Foundation, the Israel Science Foundation (ISF), the Germany-Israel Foundation for Research and Development (GIF), and the Israel Cancer Research Foundation (ICRF).

For more than a century, the Technion – Israel Institute of Technology has pioneered in science and technology education and delivered world-changing impact. Proudly a global university, the Technion has long leveraged boundary-crossing collaborations to advance breakthrough research and technologies. Now with a presence in three countries, the Technion will prepare the next generation of global innovators. Technion people, ideas and inventions make immeasurable contributions to the world, innovating in fields from cancer research and sustainable energy to quantum computing and computer science to do good around the world.

The American Technion Society supports visionary education and world-changing impact through the Technion – Israel Institute of Technology. Based in New York City, we represent thousands of US donors, alumni and stakeholders who invest in the Technion’s growth and innovation to advance critical research and technologies that serve the State of Israel and the global good. Over more than 75 years, our nationwide supporter network has funded new Technion scholarships, research, labs, and facilities that have helped deliver world-changing contributions and extend Technion education to campuses in three countries.